Long Term Study: Vaping Increases Odds of Quitting Heavy Smoking

Innovation
Jul.26.2022
A long term study carried out by researchers at Roswell Park Comprehensive Cancer Center, has found that adult heavy smokers with no plans to quit are more likely to do so when they switch to vaping regularly.

Only about 6% of all smokers included in the trial quit smoking completely, but the rates were significantly higher among those who vaped daily, at 28%.

Long Term Study: Vaping Increases Odds of Quitting Heavy Smoking

Published recently in JAMA Network Open, the study titled, “Association of e-Cigarette Use With Discontinuation of Cigarette Smoking Among Adult Smokers Who Were Initially Never Planning to Quit,” used data from 2014 to 2019 as part of the Population Assessment of Tobacco and Health (PATH) Study, a long-term study looking into tobacco use behaviour and related health patterns in the US.

 

Findings from Wave 1 of the study released in 2016, had already put to rest certain misconceptions about vaping such as the infamous Gateway Theory. When the researchers focused their analysis on a select group of 1,600 smokers who had no plans to quit smoking and were not using e-cigarettes when the study began, they found that those who went on to vape daily were the ones who managed to quit.

 

“These findings are paradigm-shifting, because the data suggest that vaping may actually help people who are not actively trying to quit smoking. Most other studies focus exclusively on people who are actively trying to quit smoking, but this study suggests that we may be missing effects of e-cigarettes by not considering this group of smokers with limited intention to stop smoking -; a group that is often at the highest risk for poor health outcomes from cigarette smoking,” said Andrew Hyland, PhD, Chair of Health Behavior at Roswell Park Comprehensive Cancer Center.

 

The study reported that only about 6% of all smokers included in the trial quit smoking completely, but the rates were significantly higher among those who vaped daily, at 28%. “While clinical trials show strong evidence that vaping can help people quit smoking, findings from real-world population studies have been mixed,” said lead study author Karin Kasza, PhD, a research scientist in the Department of Health Behavior at Roswell Park. “Our study identified a positive association between daily vaping and cigarette quitting specifically among the segment of smokers who were not planning to quit, consistent with data from clinical trials.”

CBSA discloses seizure of 212,000 nicotine pouches at Pigeon River port of entry
CBSA discloses seizure of 212,000 nicotine pouches at Pigeon River port of entry
The Canada Border Services Agency said officers inspecting an incoming vehicle at the Pigeon River port of entry in June found 212,000 nicotine pouches and seized more than 29,000 Canadian dollars (about 21,170 U.S. dollars) in currency and cheques. A CBSA spokesperson disclosed the seizure this week in a Newswatch interview about enforcement operations over the past year.
Dec.30 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11
Ireland’s Tobacco and Vape Retail Licensing Regime Takes Effect; BAT Says It Should Cover Nicotine Pouches
Ireland’s Tobacco and Vape Retail Licensing Regime Takes Effect; BAT Says It Should Cover Nicotine Pouches
Ireland’s retail licensing system took effect on Feb. 2, 2026, charging annual fees per point of sale and enforced by the Health Service Executive (HSE). British American Tobacco’s local unit, BAT Ireland, said excluding nicotine pouches could leave a regulatory gap.
Feb.04 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
2Firsts Interview | Bengt Wiberg: Why the Oral Health Risks of Nicotine Pouches Merit Further Study
2Firsts Interview | Bengt Wiberg: Why the Oral Health Risks of Nicotine Pouches Merit Further Study
As nicotine pouches gain global traction as a lower-risk alternative to smoking, questions are emerging about their potential oral health effects. In a 2Firsts interview, Stingfree AB founder Bengt Wiberg discusses why gum irritation and oral lesions warrant closer scrutiny within the broader framework of tobacco harm reduction.
Jan.06
Product | Featuring a 1.47-inch TFT color display and up to 40W output, the Aspire Fluffi Pro launches in European channels.
Product | Featuring a 1.47-inch TFT color display and up to 40W output, the Aspire Fluffi Pro launches in European channels.
Aspire, a brand under Eigate Technology, has launched the open-system Fluffi Pro on its official website. It is now available via select online channels in Switzerland, Italy, and France at around €24.5, featuring upgrades over the standard Fluffi in power and battery capacity, screen configuration, high-wattage coil specs, and a redesigned side-fill/side-airflow structure.
Jan.13 by 2FIRSTS.ai